-
2
-
-
33744958838
-
Long-term outcomes of the surgical management of renal cell carcinoma
-
DOI 10.1007/s00345-006-0055-5
-
Lam JS, Belldegrun AS, Pantuck AJ. Long-term outcomes of the surgical management of renal cell carcinoma. World J Urol 2006; 24:255-266. (Pubitemid 44138180)
-
(2006)
World Journal of Urology
, vol.24
, Issue.3
, pp. 255-266
-
-
Lam, J.S.1
Belldegrun, A.S.2
Pantuck, A.J.3
-
3
-
-
18944385751
-
Immunotherapy for advanced renal cell cancer
-
Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A,Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; CD001425.
-
(2005)
Cochrane Database Syst Rev
-
-
Coppin, C.1
Porzsolt, F.2
Awa, A.3
Kumpf, J.4
Coldman Awilt, T.5
-
4
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
DOI 10.1056/NEJMoa060655
-
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134. (Pubitemid 46089673)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
Negrier, S.7
Chevreau, C.8
Solska, E.9
Desai, A.A.10
Rolland, F.11
Demkow, T.12
Hutson, T.E.13
Gore, M.14
Freeman, S.15
Schwartz, B.16
Shan, M.17
Simantov, R.18
Bukowski, R.M.19
-
5
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
DOI 10.1056/NEJMoa065044
-
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, D.4
Bukowski, R.M.5
Rixe, O.6
Oudard, S.7
Negrier, S.8
Szczylik, C.9
Kim, S.T.10
Chen, I.11
Bycott, P.W.12
Baum, C.M.13
Figlin, R.A.14
-
6
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
DOI 10.1056/NEJMoa066838
-
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.22
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
Dutcher, J.4
Figlin, R.5
Kapoor, A.6
Staroslawska, E.7
Sosman, J.8
McDermott, D.9
Bodrogi, I.10
Kovacevic, Z.11
Lesovoy, V.12
Schmidt-Wolf, I.G.H.13
Barbarash, O.14
Gokmen, E.15
O'Toole, T.16
Lustgarten, S.17
Moore, L.18
Motzer, R.J.19
-
7
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
Hutson, T.E.4
Porta, C.5
Bracarda, S.6
-
8
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
DOI 10.1016/S0140-6736(07)61904-7, PII S0140673607619047
-
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103-2111. (Pubitemid 350296300)
-
(2007)
Lancet
, vol.370
, Issue.9605
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
Chevreau, C.7
Filipek, M.8
Melichar, B.9
Bajetta, E.10
Gorbunova, V.11
Bay, J.-O.12
Bodrogi, I.13
Jagiello-Gruszfeld, A.14
Moore, N.15
-
9
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-1068.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
Szczylik, C.4
Lee, E.5
Wagstaff, J.6
-
10
-
-
70449379934
-
Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function
-
Parsa V, Heilbrun L, Smith D, Sethi A, Vaishampayan U. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin Genitourin Cancer 2009; 7:E10-E15.
-
(2009)
Clin Genitourin Cancer
, vol.7
-
-
Parsa, V.1
Heilbrun, L.2
Smith, D.3
Sethi, A.4
Vaishampayan, U.5
-
11
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337. (Pubitemid 36109749)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.I1
, pp. 327-337
-
-
Mendel, D.B.1
Douglas Laird, A.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
Schreck, R.E.7
Abrams, T.J.8
Ngai, T.J.9
Lee, L.B.10
Murray, L.J.11
Carver, J.12
Chan, E.13
Moss, K.G.14
Haznedar, J.O.15
Sukbuntherng, J.16
Blake, R.A.17
Sun, L.18
Tang, C.19
Miller, T.20
Shirazian, S.21
McMahon, G.22
Cherrington, J.M.23
more..
-
12
-
-
65249140620
-
A phase i mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects
-
Abstract 9072 Los Angeles California USA: AACR;
-
Bello CL, Patyna S, Kang P, Klamerus K. A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects. In: Annual Meeting of the American Association for Cancer Research. Los Angeles, California, USA: AACR; 2007. Abstract 9072.
-
(2007)
Annual Meeting of the American Association for Cancer Research
-
-
Bello, C.L.1
Patyna, S.2
Kang, P.3
Klamerus, K.4
-
14
-
-
80051509196
-
-
Wyeth Pharmaceuticals Inc. Rev September of 22
-
Temsirolimus prescribing information booklet. Wyeth Pharmaceuticals Inc. Rev September 2010; page 17 of 22.
-
(2010)
Temsirolimus Prescribing Information Booklet
, pp. 17
-
-
-
15
-
-
34548787904
-
Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study
-
DOI 10.1002/cncr.22904
-
Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376-1384. (Pubitemid 47435612)
-
(2007)
Cancer
, vol.110
, Issue.6
, pp. 1376-1384
-
-
Launay-Vacher, V.1
Oudard, S.2
Janus, N.3
Gligorov, J.4
Pourrat, X.5
Rixe, O.6
Morere, J.-F.7
Beuzeboc, P.8
Deray, G.9
-
16
-
-
0035818877
-
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
-
DOI 10.1056/NEJMoa003013
-
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655-1659. (Pubitemid 33126820)
-
(2001)
New England Journal of Medicine
, vol.345
, Issue.23
, pp. 1655-1659
-
-
Flanigan, R.C.1
Salmon, S.E.2
Blumenstein, B.A.3
Bearman, S.I.4
Roy, V.5
McGrath, P.C.6
Caton Jr., J.R.7
Munshi, N.8
Crawford, E.D.9
-
17
-
-
0033542845
-
Cancer in patients on dialysis for end-stage renal disease: An international collaborative study
-
DOI 10.1016/S0140-6736(99)06154-1
-
Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354:93-99. (Pubitemid 29313142)
-
(1999)
Lancet
, vol.354
, Issue.9173
, pp. 93-99
-
-
Maisonneuve, P.1
Agodoa, L.2
Gellert, R.3
Stewart, J.H.4
Buccianti, G.5
Lowenfels, A.B.6
Wolfe, R.A.7
Jones, E.8
Disney, A.P.S.9
Briggs, D.10
McCredie, M.11
Boyle, P.12
-
18
-
-
70349233039
-
Sunitinib treatment in patients with severe renal function impairment: A report of four cases by the hellenic cooperative oncology group
-
Lainakis G, Bamias A, Psimenou E, Fountzilas G, Dimopoulos MA. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the hellenic cooperative oncology group. Clin Nephrol 2009; 72:73-78.
-
(2009)
Clin Nephrol
, vol.72
, pp. 73-78
-
-
Lainakis, G.1
Bamias, A.2
Psimenou, E.3
Fountzilas, G.4
Ma, D.5
-
19
-
-
49849101828
-
Sorafenib: Tolerance in patients on chronic hemodialysis: A single-center experience
-
Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 2008; 74:245-246.
-
(2008)
Oncology
, vol.74
, pp. 245-246
-
-
Rey, P.M.1
Villavicencio, H.2
-
20
-
-
34147205677
-
Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values
-
DOI 10.1373/clinchem.2006.077180
-
Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53:766-772. (Pubitemid 46580250)
-
(2007)
Clinical Chemistry
, vol.53
, Issue.4
, pp. 766-772
-
-
Levey, A.S.1
Coresh, J.2
Greene, T.3
Marsh, J.4
Stevens, L.A.5
Kusek, J.W.6
Van Lente, F.7
-
21
-
-
23044448585
-
Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)z
-
DOI 10.1111/j.1523-1755.2005.00365.x
-
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2005; 67:2089-2100. (Pubitemid 41623371)
-
(2005)
Kidney International
, vol.67
, Issue.6
, pp. 2089-2100
-
-
Levey, A.S.1
Eckardt, K.-U.2
Tsukamoto, Y.3
Levin, A.4
Coresh, J.5
Rossert, J.6
De Zeeuw, D.7
Hostetter, T.H.8
Lameire, N.9
Eknoyan, G.10
Willis, K.11
-
22
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer Eawanders, J.3
Kaplan, R.S.4
Rubinstein, L.5
-
24
-
-
77954843443
-
Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function
-
Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010; 50:472-481.
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 472-481
-
-
Khosravan, R.1
Toh, M.2
Garrett, M.3
La Fargue, J.4
Ni, G.5
Marbury, T.C.6
-
25
-
-
84888443122
-
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis 2009
-
Orlando, FL 2009. p. J Clin Oncol (Supplement; abstr 5109)
-
Josephs D, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis. In: 2009. ASCO Annual Meeting. Orlando, FL 2009. p. J Clin Oncol 27:15 s (Supplement; abstr 5109).
-
ASCO Annual Meeting
, vol.27
-
-
Josephs, D.1
Hutson, T.E.2
Pickering, L.M.3
Larkin, J.M.4
Choueiri, T.K.5
Patel, T.V.6
-
26
-
-
55049136730
-
Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies
-
Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13:1084-1096.
-
(2008)
Oncologist
, vol.13
, pp. 1084-1096
-
-
Hutson, T.E.1
Figlin, R.A.2
Kuhn, J.G.3
Motzer, R.J.4
-
27
-
-
38549156660
-
Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure [2]
-
DOI 10.1159/000112828
-
Inauen R, Cathomas R, Boehm T, Koeberle D, Pestalozzi BC, Gillessen S, et al. Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Oncology 2007; 72:209-210. (Pubitemid 351161612)
-
(2007)
Oncology
, vol.72
, Issue.3-4
, pp. 209-210
-
-
Inauen, R.1
Cathomas, R.2
Boehm, T.3
Koeberle, D.4
Pestalozzi, B.C.5
Gillessen, S.6
Von Moos, R.7
-
28
-
-
33847677121
-
Pharmacokinetics of bevacizumab in haemodialysis
-
Garnier-Viougeat N, Rixe O, Paintaud G, Ternant D, Degenne D, Mouawad R, et al. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant 2007; 22:975.
-
(2007)
Nephrol Dial Transplant
, vol.22
, pp. 975
-
-
Garnier-Viougeat, N.1
Rixe, O.2
Paintaud, G.3
Ternant, D.4
Degenne, D.5
Mouawad, R.6
-
29
-
-
77950952997
-
Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicenter, randomized trial
-
Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010; 89:864-872.
-
(2010)
Transplantation
, vol.89
, pp. 864-872
-
-
Gullestad, L.1
Iversen, M.2
Mortensen, S.A.3
Eiskjaer, H.4
Riise, G.C.5
Mared, L.6
-
30
-
-
34548686826
-
MTOR Inhibitors: Do They Help Preserve Renal Function?
-
DOI 10.1016/j.transproceed.2007.06.066, PII S0041134507007828
-
Moro J, Almenar L, Martinez-Dolz L, Aguero J, Rueda J, Arnau MA, et al. mTOR inhibitors: do they help preserve renal function? Transplant Proc 2007; 39:2135-2137. (Pubitemid 47418173)
-
(2007)
Transplantation Proceedings
, vol.39
, Issue.7
, pp. 2135-2137
-
-
Moro, J.1
Almenar, L.2
Martinez-Dolz, L.3
Aguero, J.4
Rueda, J.5
Arnau, M.A.6
Izquierdo, M.7
Cano, O.8
Sanchez-Lazaro, I.9
Salvador, A.10
|